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In order to be defined as a stem cell, a cell must be able 
to divide to ensure self-renewal, and to differentiate 
(Fig. 1). The earliest stem cell from a developmental 
perspective is the fertilised egg (zygote) (Fig. 2). 
The zygote is totipotent, i.e. it is capable of giving rise to all of the 
extraembryonic and embryonic tissues of the developing embryo. As 
development progresses, the differentiation potential of successive 
populations of stem cells becomes restricted, and cells are said to 
be pluripotent, multipotent and finally unipotent. Progenitor cells 
have a limited number of cell divisions and may be multipotent or 
unipotent.
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One of the most exciting areas of medical research involves the use of stem cells for the treatment of patients with a variety of diseases and for tissue 
repair. Although stem cell research is accelerating rapidly in many countries, it has in the past been limited in South Africa (SA); very little has been 
done in this country to explore the great potential offered by stem cells to address the high disease burden. Stem cell therapy has however been 
practised for many years, in SA and worldwide, in the form of haematopoietic stem cell transplantation, mainly for haematological malignancies. 
From a therapeutic perspective, two types of stem cells can be defined: pluripotent stem cells and adult stem cells. Pluripotent cells derived 
from the inner cell mass of blastocysts (either from in vitro fertilisation or following somatic cell nuclear transfer) are called embryonic 
stem (ES) cells, while those derived by reprogramming adult cells are called induced pluripotent stem (iPS) cells. Adult stem cells include 
haematopoietic, mesenchymal and neural stem cells.
The purpose of this article is to critically examine the SA legislation with regard to elements that impact on pluripotent stem cell research 
and the use of pluripotent stem cells for therapeutic purposes. This includes (but is not limited to) legislation from the National Health Act 
(Chapter 8 in particular) and its regulations, and deals with matters related to research on embryos in the stem cell context, somatic cell 
nuclear transfer, reproductive and therapeutic cloning and the generation and therapeutic use of iPS and ES cells.
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Fig. 1. Definition of a stem cell. In order to be defined as a stem cell, a cell must 
be able to divide and to differentiate. To ensure a continuing source of cells 
capable of self-renewal, at least one of the resulting daughter cells should remain 
a stem cell.
Fig. 2. From fertilisation to blastocyst formation. A zygote results from the 
fertilisation of an egg by a sperm. After three rounds of division, an 8-cell 
embryo can be recognised, and following compaction and morula formation 
this goes on to form a blastocyst. The blastocyst consists of an inner cell mass 
which goes on to develop into the embryo proper, while the outer layer, the 
trophoblast, goes on to form the placenta. Micrographs in the lower half of the 
figure were provided by Prof. Carin Huyser (Reproductive Biology Laboratory, 
Department of Obstetrics and Gynaecology, University of Pretoria and Steve 
Biko Academic Hospital, Pretoria, South Africa).
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The adult human is made up of approximately 
4×1013 cells,[1] and there are more than 200 
different cell types in the human body. 
Approximately 200 million (2×108 ) cells are 
lost from the body of an adult per minute, 
and their replacement is assured by adult 
stem cells throughout life. Adult stem cells are 
found in most tissues including bone marrow, 
skin, skeletal muscle, intestinal mucosa, liver 
and neural tissue. With the exception of 
haematopoietic stem cells (HSCs), these cells 
are limited in number, are difficult to isolate 
and their therapeutic potential remains largely 
undefined. HSCs derived from the bone marrow, 
peripheral blood (following growth factor 
mobilisation of bone marrow cells) or neonatal 
blood (harvested immediately after birth via 
the umbilical cord from the placenta) have 
been used successfully and for several decades 
for haematopoietic stem cell transplantation 
(HSCT) for the treatment of neoplastic, 
haematological and genetic diseases. 
Pluripotent stem cells, the topic of this 
article, are on the other hand more complex 
with regard to their derivation, and in some 
cases are associated with important ethical 
considerations. Their therapeutic potential 
is only beginning to be explored. Table 1 
highlights the salient differences between 
adult and pluripotent stem cells.
Pluripotent stem cells include embryonic 
stem cells (ES cells) and induced pluripotent 
stem cells (iPS cells). ES cells are derived from 
the inner cell mass (ICM) of the blastocyst. 
Blastocysts are obtained either from IVF 
or following the process of somatic cell 
nuclear transfer (SCNT). The iPS cells are 
derived from adult cells which are induced 
to dedifferentiate following the introduction 
of genes which code for transcription factors 
involved in early embryonic development 
(Fig. 3). The derivation of pluripotent stem 
cells is summarised in Table 2.
ES and iPS cells can develop into almost 
every cell type in the body (hence their 
categorisation as pluripotent). ES and iPS cells 
have great potential value for understanding 
disease processes, for drug screening 
and potentially for therapeutic purposes, 
although the latter is only beginning to be 
defined. However, ES cells, irrespective of 
the means through which they are derived, 
are the source of much controversy, since 
their isolation is interpreted by some as 
necessitating the destruction of life.
Finally, it should be noted that the 2012 
Nobel Prize in physiology or medicine was 
awarded jointly to John B Gurdon and Shinya 
Yamanaka for the discovery that mature cells 
can be reprogrammed to become pluripotent.[2]
Removal and/or 
withdrawal and use of 
human tissue, blood, 
blood products and 
gametes
Section 56 of Chapter 8 of the National Health 
Act (NHA)[3] entitled ‘Use of tissue, blood, blood 
products or gametes removed or withdrawn 
from living persons’, stipulates in subsection 
(1) that ‘[a] person may use tissue or gametes 
removed or blood or a blood product withdrawn 
from a living person only for such medical or 
dental purposes as may be prescribed’. The 
interpretation of ‘prescribed’ is understood to 
mean established medical practice. Where this 
is not the case, it is understood that any other 
‘purposes’ would first need to be validated in the 
context of a clinical trial.[4]
Subsection (2) stipulates that ministerial 
authorisation is needed for removal or 
withdrawal of tissue, blood, blood products 
or gametes from a living person under the 
following conditions:
‘(i) Tissue, blood, a blood product or a gamete 
from a person who is mentally ill within the 
meaning of the Mental Health Care Act, 2002 
(Act No. 17 of 2002);
(ii) tissue which is not replaceable by natural 
processes from a person younger than 18 years;
(iii) a gamete from a person younger than 18 
years; or
(iv) placenta, embryonic or foetal tissue, stem 
cells and umbilical cord, excluding umbilical 
cord progenitor cells.’
In the context of this article, the removal 
and/or withdrawal of the following from a 
living person therefore requires ministerial 
authorisation:
• Embryonic tissue (from conception to 8 
weeks of gestation)
• Fetal tissue (from 9 weeks following 
conception to birth)
• Stem cells
• Placenta and umbilical cord.
Table 1. Adult v. pluripotent stem cells
Adult Differentiation potential generally limited 
to cells of tissue in which they reside
Readily available
No ethical issues
No evidence for tumorigenesis
Therapeutic value well demonstrated HSCs for bone marrow transplantation
MSCs: >500 registered clinical trials
Pluripotent Differentiation potential:  all of the 
body’s cell types
Technically more difficult to obtain
Ethical issues related to ES cells
Potential for tumorigenesis
Therapeutic value – remains to be 
determined
Value: understanding disease 
processes, drug screening                               
MSCs = mesenchymal stem cells





Embryonic stem cell Blastocyst Derived from IVF Yes
Derived by SCNT 
(therapeutic cloning)
Yes
Induced pluripotent stem cell Somatic cell No
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Specifically excluded from this requirement are umbilical progenitor 
cells. The reason for this exclusion probably relates to the regulator’s 
understanding that stem cells from cord blood used in HSCT are limited 
to progenitor cells. There are, however, more primitive stem cells in 
cord blood, which are not progenitors that are likely to contribute 
to the success of engraftment following transplantation, as well as 
non-haematopoietic stem cells.[5] It is therefore understood that the 
removal and/or withdrawal of these cells would also require ministerial 
authorisation, since they are not specifically excluded. Since it is at 
present not possible to separate progenitors from the other stem cells on 
a routine basis, we would therefore interpret this to mean that removal 
and/or withdrawal of cord blood requires ministerial authorisation.
Research on embryos in the stem cell 
context
A human embryo is the product of a fertilised egg, from the zygote until 
the fetal stage[6] or ‘the developing organism from fertilization to the end 
of the eighth week.[7] A further distinction is made for the period from 
fertilisation until 14 days which is referred to as the pre-embryonic (or 
pre-implantation) stage.[8] Fourteen days after fertilisation also marks the 
stage at which an embryo begins to develop a nervous system.[9]
In 2002 the House of Lords in the UK published a report on stem cell 
research.[10] Chapter 4 which deals with ‘The Status of the Early Embryo’ is in 
line with the previous recommendations of the 1984 Warnock Committee 
Report[11] and concludes that ‘Whilst respecting the deeply held views 
of those who regard any research involving the destruction of a human 
embryo as wrong and having weighed the ethical arguments carefully, 
the Committee is not persuaded, especially in the context of the current 
law and social attitudes, that all research on early human embryos should 
be prohibited … If the respect to be accorded to an embryo increases as 
it develops, this is a gradual process and it may be difficult to establish 
precisely the point of transition from one stage to the next. The [Human 
Fertilisation and Embryology] 1990 Act established 14 days as the limit 
for research on early embryos. Fourteen days has an objective justification 
insofar as it represents the stage at which the primitive streak, the precursor 
of the development of a nervous system, begins to appear. This limit seems 
to have been widely accepted, and the research done under the Act under 
licence from the HFEA [Human Fertilisation and Embryology Authority] 
has attracted very little criticism from those who accept the case for 
research on early embryos. We have received no evidence to suggest that, 
if research on human embryos is to continue, there should be a different 
limit. In point of fact the stage at which stem cells need to be extracted for 
research is very much earlier than that – at the blastocyst stage – when 
the early embryo is still smaller than a pinhead. The Committee considers 
that 14 days should remain the limit for research on early embryos’. The 
14 day limit was also recommended by the Waller Committee in Victoria, 
Australia, in 1984.[12]
With regard to definitions in the South African legislation, an embryo 
is defined in the NHA as ‘a human offspring in the first eight weeks from 
conception’ (Annexure). Use of the word offspring is not appropriate 
and we would suggest replacing the definition with ‘the early stages of 
human growth and development, from conception to the eighth week’.
Removal and/or withdrawal of tissue from a living human embryo 
requires ministerial authorisation. Tissue is defined in the NHA as ‘human 
tissue, and includes flesh, bone, a gland, an organ, skin, bone marrow 
or body fluid, but excludes blood or a gamete’,  and in the Regulations 
Relating to Tissue Banks[13] as ‘a functional group of cells. The term is used 
collectively in the Regulations to indicate both cells and tissue’.
Subsection 57(4)  of Chapter 8 of the NHA stipulates that ‘[t]he 
Minister may permit research on stem cells and zygotes which are 
not more than 14 days old on a written application and if (a) the 
applicant undertakes to document the research for record purposes; 
and (b) prior consent is obtained from the donor of such stem cells or 
zygotes’. It is presumed that ‘cells and zygotes’ should be interpreted 
as a pre-embryo, as defined above. The Act is however silent on 
research on embryos from 14 days to 8 weeks of gestation.
Section 57(3) provides that ‘[n]o person may import or export human 
zygotes or embryos without the prior written approval of the Minister’.
In summary, removal and/or withdrawal of tissue from a living 
human embryo requires ministerial authorisation. It is not clear, 
however, whether ‘use’ of this tissue, once removed from a 3-8 week 
embryo, requires ministerial authorisation. Irrespective, such ‘use’ will 
require the approval of a registered research ethics committee.
Somatic cell nuclear transfer
The procedure of SCNT can be described as the removal of the 
chromosomes (constituted as the meiotic spindle complex) from an 
oocyte, followed by the transfer and fusion of a donor somatic cell 
nucleus to the enucleated oocyte. The manipulated oocyte is then 
artificially activated which should induce subsequent development of 
the embryo (Fig. 4).
Fig. 3. Induced pluripotent stem (iPS) cells. iPS cells are derived from 
differentiated human somatic cells which are reprogrammed (dedifferentiated) 
to a pluripotent state. This is achieved by the introduction and expression of 4 
transcription factors – Oct4, Sox2, Klf4 and c-Myc – into the somatic cells of 
interest.
Fig. 4. Somatic cell nuclear transfer (SCNT). SCNT involves the removal of 
the chromosomes (constituted as the meiotic spindle complex) from an oocyte, 
followed by the transfer and fusion of a donor somatic cell nucleus to the 
enucleated oocyte. The manipulated oocyte is then artificially activated which 
should induce subsequent development of the embryo.
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SCNT is currently being performed in several laboratories worldwide 
for the purpose of creating human stem cells. In the UK for example, 
human SCNT research is legal and in 2001 was incorporated into 
the Human Fertilisation and Embryology Act 1990 (HFEA). However, 
before performing SCNT it is necessary to obtain permission from the 
HFEA. In the USA, SCNT research is also legal but may not be funded by 
the federal government as a result of the Dickey-Wicker Amendment 
bill passed in 1995. The Department of Health and Human Services 
and the National Institutes of Health prohibits the use of funds for 
research studies involving the creation of human embryos and the 
destruction thereof. SCNT research aimed at producing human ES 
cells may nonetheless be legally performed when funded by private 
or non-governmental organisations. 
Strict regulation of human SCNT research should be maintained by 
registered research ethics committees, as well as by ethical guidelines that 
have been set by the US National Academy of Science, the International 
Society for Stem Cell Research (ISSCR), and the American Society for 
Reproductive Medicine.[14] As reviewed by Cervera and Mitalipov,[15] there 
are several ethical and legal issues associated with SCNT, one of the most 
important of which is access to human oocytes. The ideal approach 
would be to identify donors willing to provide oocytes for research 
without any reimbursement. According to one study, however, women 
are simply not prepared to undergo ovarian stimulation and invasive 
oocyte retrieval without being reimbursed for their efforts.[16]
The ISSCR ‘Position Statement on the Provision and Procurement of 
Human Eggs for Stem Cell Research’[17] recommends that ‘[p]aying (in cash 
or kind) women for providing eggs for research is ethically justifiable as a 
means of compensating them for their time, inconvenience, willingness 
to accept some risks, and reimbursement for out-of-pocket expenses. 
This is not a payment for the eggs themselves’. Other observations and/
or recommendations include the unethical nature of using financial 
incentives to induce donation, the need for review by a registered 
research ethics committee, the need to separate fertility treatments from 
egg donation, the need for standard operating procedures in accredited 
institutions and for donor follow-up after donation, and vigilance with 
regard to cross-border donation and trafficking. Local laws regulating 
compensation for oocyte donors may also govern the procurement of 
human oocytes for research purposes. In California, for example, patients 
donating oocytes for research purposes are covered for certain expenses 
but are not reimbursed for ‘time, effort and inconvenience’. In Oregon, 
on the other hand, research oocyte donors are fully compensated in a 
manner that is equal to reproductive oocyte donors. [18] 
With regard to the situation in South Africa, subsection 60(1)(a) 
of Chapter 8 of the NHA, entitled ‘Payment in connection with the 
importation, acquisition or supply of tissue, blood, blood products or 
gametes’, stipulates that ‘a hospital or an institution contemplated in 
section 58(1)(a), a person or an institution contemplated in section 
63 and an authorised institution or, in the case of tissue or gametes 
imported or exported in the manner provided for in the regulations, 
the importer or exporter concerned, may receive payment in respect of 
the acquisition, supply, importation or export of any tissue or gamete 
for or to another person for any of the purposes contemplated in 
section 56 or 64’. This is further detailed in subsections (2), (3), (4) and 
(5) as follows:
‘(2)    The amount of payment contemplated in subsection (1) may not 
exceed an amount which is reasonably required to cover the costs 
involved in the importation, export, acquisition or supply of the tissue, 
gamete, blood or blood product in question.
(3)   This section does not prevent a health care provider registered with 
a statutory health professional council from receiving remuneration for 
any professional service rendered by him or her.
(4)  It is an offence for a person
(a) who has donated tissue, a gamete, blood or a blood product to receive 
any form of financial or other reward for such donation, except for the 
reimbursement of reasonable costs incurred by him or her to provide such 
donation; and
(b) to sell or trade in tissue, gametes, blood or blood products, except as 
provided for in this Chapter.
(5)  Any person convicted of an offence in terms of subsection (4) is liable 
on conviction to a fine or to imprisonment for a period not exceeding five 
years or to both a fine and such imprisonment.’
Further guidance regarding the legal position relating to egg 
donation in South Africa is found in the Regulations Relating to 
Artificial Fertilisation of Persons.[19] A gamete donor ‘means a living 
person from whose body a gamete or gametes are removed or 
withdrawn, for the purpose of artificial fertilisation’. With regard to 
compensation, clause 4 states that ‘[a] person from whose body a 
gamete has been removed or withdrawn may be reimbursed for 
any reasonable expenses incurred by him or her in order to donate 
a gamete as contemplated in section 60(4)(a) of the (National Health) 
Act’. Clauses 6 and 7 stipulate that only six children may be conceived 
through artificial fertilisation from a single gamete donor. 
It should be noted that the NHA and the regulations are silent 
regarding egg donation for research purposes.
Further details regarding payment are provided in the 2008 
guidelines of the Southern African Society for Reproductive Medicine 
and Gynaecological Endoscopy (SASREG).[20] With regard to payment 
of oocyte donors, the guidelines state that ‘[m]onetary compensation 
of the donor should reflect the time, inconvenience, financial costs 
to the donor – e.g. travel, loss of income and childcare costs, physical 
and emotional demands and risks associated with oocyte donation 
and should be at a level that minimizes the possibility of undue 
inducement of donors and the suggestion that payment is for the 
oocytes themselves. The monetary compensation should not be 
predicated on the clinical outcome (no. of oocytes or pregnancy 
outcome) but rather on fair compensation for the procedure of 
donating eggs […] Donors should only receive financial compensation 
via fertility clinics and not receive any compensation directly from the 
recipients or other third parties’. In an amendment of 25 November 
2014 it is stipulated that ‘[e]gg donors should not be compensated 
more than R7 000 per procedure from 1 January 2015’.[21]
As a result of the ethical and financial limitations related to 
reimbursement of oocyte donors, alternative sources of human 
oocytes have been investigated for SCNT research. Immature oocytes, 
which are generally discarded in assisted reproductive procedures, 
are voluntarily donated by patients for research purposes. However, in 
vitro maturation, fertilisation, and subsequent development of these 
immature oocytes to the blastocyst stage are highly compromised 
following SCNT, and are therefore not appropriate for optimisation of 
the SCNT procedure.[22,23] 
It should be noted that the use of high-quality human oocytes in 
SCNT does not guarantee successful embryo development to the 
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blastocyst stage. In a study conducted by Noggle and colleagues,[24] 
successful blastocyst development and subsequent isolation of 
ESCs was only observed in those embryos that had somatic cells 
transferred to non-enucleated oocytes. This observation may have 
implied that molecules essential for proper reprogramming of 
the somatic cell nucleus might be removed during enucleation, 
which are supposedly retained by the presence of the oocyte’s own 
chromosomes. Another study that observed early failure in monkey 
SCNT embryo development, also assumed that the cause was related 
to the removal of reprogramming factors during enucleation possibly 
linked to the oocyte’s chromosomes.[25] Subsequent studies have 
however proven otherwise, namely that the oocyte’s chromosomes 
are not a prerequisite for the successful reprogramming of the somatic 
cell nuclear genome.[26] Nevertheless, many studies encourage that 
each step in SCNT be thoroughly optimised and adapted specifically 
for human oocytes. In summary, a major drawback related to rigorous 
testing on human oocytes is the requirement of a large number of 
good quality human oocytes, which remains limited.[11] 
From an ethical point of view, the intentional creation of embryos 
using SCNT is condemned for a variety of reasons. It is seen to diminish 
human individuality and integrity, and the freedom, identity and 
dignity of the human person (in the sense that many identical copies 
of the same DNA may be created). It could also be viewed as impacting 
on human reproductive autonomy, as an embryo is created with 
only one genetic parent to whom the embryo would be genetically 
identical. Researchers should be cognizant of these concerns, which 
are fundamental to our understanding of humanity, human identity, 
the inviolability of the human person, human reproduction and 
human dignity. Global consensus on the ban of reproductive cloning 
in the form of the UN Declaration on Human Cloning (2005)[27] has 
unfortunately cast a shadow on the use of SCNT in the context of 
‘therapeutic cloning’, incorrectly equated with ‘reproductive cloning’. 
Reproductive and therapeutic cloning
Blastocysts derived by SCNT can be utilised in two ways (Fig. 5). In the 
first, the blastocyst is placed in the uterus of a surrogate mother and if 
development occurs to term, the resulting offspring will be identical 
to the somatic cell donor and will have been derived by a process 
referred to as ‘reproductive cloning’. In the second, cells derived from 
the ICM of the blastocyst are grown in tissue culture to form ES cells. 
This process is referred to as ‘therapeutic cloning’ since the ES cells are 
autologous as the nuclear genome of these cells is identical to that of 
the somatic cell donor. (Note that the mitochondrial genome will be 
a mosaic between the oocyte donor and the somatic cell donor). Use 
of these cells in the donor would not require immunosuppression, as 
would be the case if the cells were allogeneic.
Reproductive cloning of a human being is defined in subsection 
57(6)(a)  of Chapter 8 of the NHA as ‘the manipulation of genetic 
material in order to achieve the reproduction of a human being 
and includes nuclear transfer or embryo splitting for such purpose’ 
(Annexure). We would suggest replacing this with ‘the manipulation 
of cells, gametes, zygotes or embryos or genetic material derived 
therefrom in order to achieve reproduction of a human being and 
includes but is not limited to nuclear transfer and embryo splitting’.
Subsection 57(1) of Chapter 8 of the NHA, entitled ‘Prohibition of 
reproductive cloning of human beings’, stipulates that a person may 
not
‘(a) manipulate any genetic material, including genetic material of 
human gametes, zygotes or embryos; or
(b) engage in any activity, including nuclear transfer or embryo splitting,
for the purpose of the reproductive cloning of a human being.’
Therapeutic cloning is defined in section 57(6)(b) of Chapter 8 of the 
NHA as ‘the manipulation of genetic material from either adult, zygotic 
or embryonic cells in order to alter, for therapeutic purposes, the 
function of cells or tissues’ (Annexure). This definition is problematic 
as it is much broader and less specific than the recognised procedure 
for reproductive cloning, which as described above is SCNT. We would 
recommend the inclusion of SCNT in the definition.
In contrast to reproductive cloning, subsection 57(2) of Chapter 8 
of the NHA provides that ‘[t]he Minister may, under such conditions 
as may be prescribed, permit therapeutic cloning utilising adult or 
umbilical cord stem cells’.
According to subsection 57(5)  of Chapter 8 of the NHA, ‘[a]ny 
person who contravenes a provision of this section or who fails to 
comply therewith is guilty of an offence and is liable on conviction to 
a fine or to imprisonment for a period not exceeding five years or to 
both a fine and such imprisonment’.
In summary, reproductive cloning is banned in SA. Therapeutic 
cloning is permitted but requires ministerial authorisation since this 
involves ‘research on stem cells and zygotes which are not more than 
14 days’. This is summarised in Table 2.
Embryonic stem cells
Embryonic stem cells are derived from the ICM of the blastocyst. 
In humans, the blastocyst is equivalent to a 5-day-old embryo. 
The ICM, which consists of approximately 100 cells, is manually 
removed from the (pre-)embryo and is placed in tissue culture under 
specific conditions.[28] The resulting cells are termed ES cells and are 
pluripotent in nature.
Two methods can be used to obtain a blastocyst. The first is IVF and 
the second is SCNT (discussed above).
Fig. 5. Reproductive and therapeutic cloning. Blastocysts derived by SCNT 
can be utilised in two ways. In the first, the blastocyst is placed in the uterus 
of a surrogate mother and if development occurs to term, the resulting 
offspring will have been derived by a process referred to as ‘reproductive 
cloning’. In the second, cells derived from the ICM of the blastocyst are 
grown in tissue culture to form ES cells. The nuclear genome of these cells 
is identical to that of the somatic cell donor. This process is referred to as 
‘therapeutic cloning’.
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There are several views as to when human life begins. These include:
• at the moment of fertilisation
• with the development of the first organ system (heart and blood 
vessels)
• at the moment of perceived consciousness
• from the moment the fetus is able to survive outside the uterus 
(22-24 weeks).
These perceptions may explicitly or implicitly influence considerations 
relating to the possible uses, creation and ‘destruction’ of human 
embryos for research purposes, more so when research activities 
involving the human embryo are legally defined. As described in the 
section on Research on embryos in the stem cell context above, the 
14-day limit following fertilisation, after which embryos may not be 
permitted to develop further in vitro, is commonly accepted. 
For those who believe that life begins at the moment of fertilisation, 
preparation of ES cells would be tantamount to destroying a human 
life. This is the source of the controversy surrounding ES cells. 
Secondly, the source of these human embryos or ES cells is also 
relevant. For example, in the case of embryos, were they created 
solely for research purposes or were they excess embryos left over 
after IVF treatment? If not used and destined to be discarded in any 
event, a strong argument could be advanced that it may be morally 
justifiable to use them in medical research aimed at ultimately 
benefiting the greater collective.
From a legislative point of view, the preparation of human ES cells 
and all research involving these cells requires ministerial authorisation 
in SA.
Induced pluripotent stem cells
Induced pluripotent stem cells are derived from differentiated 
human somatic cells which are reprogrammed (dedifferentiated) to a 
pluripotent state. This is achieved by the introduction and expression 
of four transcription factors – Oct4, Sox2, Klf4 and c-Myc – into the 
somatic cells of interest.[29] Reprogramming is a universal process, 
and has been done in mesodermal, endodermal and ectodermal 
derivatives including fibroblasts, lymphocytes, liver, stomach, beta 
cells and neural progenitor cells from a variety of species.
Like ES cells, human iPS cells have the potential to develop into 
any of the body’s cell types and are therefore pluripotent in nature. 
iPS cells are however easier to produce than ES cells, and are not 
associated with the same controversial embryonic source, as the 
procedure does not involve the use of human embryos or oocytes. 
Obtaining somatic cells (e.g. through a skin biopsy) is also non-
invasive, compared to the donation of oocytes used in the SCNT 
procedure. 
One of the primary legal concerns associated with the 
procurement of iPS cells is the issue of the (genetic) privacy of 
the cell donor. Unauthorised or inappropriate disclosure of the 
donor’s genetic information holds specific ethical, legal, social and 
economic risks. Researchers should take special care to protect the 
privacy interests of donors, for example by measures that will control 
cross-referencing of information to public databases. The issue 
of incidental findings also arises, which concerns the inadvertent 
discovery of a donor’s genetic predisposition to a specific condition 
or disease by the researcher. The question arises as to how to deal 
with these findings.[30] Informed consent, specifically the withdrawal 
of consent, poses another challenge. iPS cell lines may also be 
used indefinitely for future research, which poses an obstacle with 
regard to voluntary informed consent by research participants. For 
example, with regard to the various uses of cell lines, donors may 
morally object to the derivation of human gametes or the creation 
of human-animal chimeras. The conventional rule that a research 
participant may withdraw his or her participation at any time during 
the research is another challenge in this context. If an iPS cell line 
has been created, may a donor withdraw his or her consent to 
participate in the research? If so, the consequences for the relevant 
researcher may be far-reaching.[30]
Further concerns that have been mentioned relate to possible 
downstream uses of the iPS cell derivates, which may include the 
genetic modification of the cells; large scale genomic sequencing; 
the sharing of cell lines among researchers; the commercialisation 
of applications involving the cells; and the possibility of deriving 
gametes in vitro from IPS cells.[31] 
With regard to the derivation of gametes, the potential of iPS cells 
to differentiate into both male and female germ cells in different 
species, including the development of gametes and offspring in 
mice, has already been demonstrated.[32,33] This gives rise to intricate 
legal and ethical issues relating to the sequence and process of 
reproduction and genetic parentage, not to mention informed 
consent issues, concerns regarding cloning, as well as the potential 
to create an embryo by donors who may have no knowledge of such 
possibility or attempt.
Genome editing of pre-implantation 
embryos
Genome editing is the precise and intentional modification 
of nucleotide sequences in a genome, and has been used 
successfully in stem cells (including pluripotent stem cells) 
and adult somatic cells. DNA is inserted, removed or replaced 
at specific predetermined sites using artificially engineered 
nucleases or ‘molecular scissors’. Engineered nucleases include 
zinc finger nucleases (ZFN), transcription activator-like effector 
nucleases (TALEN) and clustered regularly interspaced short 
palindromic repeats (CRISPR)-Cas9. The ability to treat and/or 
cure human diseases such as HIV/AIDS, haemophilia, sickle-cell 
anaemia and several forms of cancer using this technology has 
generated a great deal of excitement. However, the ability to alter 
the genome in gametes (sperm, eggs), zygotes (fertilised eggs) 
and early embryos has raised a great deal of concern.[34, 35] This is 
in part due to the limited knowledge, unpredictable nature and 
unintended consequences accompanying ‘on-target’ intended 
effects, as well as ‘off-target’ effects,  which involve unintended 
gene editing at sites other than those targeted. These changes 
will be passed on to subsequent generations and the potential 
consequences to the individual, their families and society as a 
whole will need to be carefully considered. In addition, there is 
the fear that unscrupulous individuals may move towards unsafe 
or unethical uses of the technology.
Liang et al.[36] have recently published the first set of experiments 
performed on early human embryos. They found that although the 
target gene (b-globin or HBB) was effectively cleaved, the efficiency 
was low and the resultant embryos were mosaic. Off-target effects 
were also observed. These findings confirm and highlight the need 
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to proceed with great caution in human gametes, zygotes and 
embryos. 
In a highly laudable form of ‘self-regulation’, the global scientific, 
medical, legal and ethics communities have recommended that the 
use of these technologies in gametes, zygotes and early embryos in 
humans be put on hold until there is a greater appreciation of their 
consequences. The community has called for regulatory measures to 
be put into place, for the initiation of an open public debate and for 
open and transparent research which is subjected to peer review.
Clinical translation
The clinical translation of research conducted on pluripotent stem 
cells is clearly of immense interest. Safety issues relate in part to the 
ability of these cells to divide in an autonomous manner, and the 
ability of these cells to form tumours has been well described.
With regard to ES cells (irrespective of their mode of derivation), 
clinical trials have to date been limited. One clinical trial has been 
conducted for spinal cord injury using ES cell-derived oligodendrocyte 
precursors. This trial was terminated prematurely after treating five 
patients and has been the subject of much debate.[37] Long-term 
follow-up of these patients has revealed no clinical improvement 
or adverse effects related to the treatment. Other clinical trials have 
utilised ES cell-derived retinal pigment epithelial (RPE) cells for the 
treatment of a variety of retinal disorders, including age-related 
macular degeneration. Results to date have revealed possible clinical 
improvement with no adverse effects related to the treatment.[38]
With regard to iPS cells, which are a much more recent discovery 
than ES cells, a single clinical trial is underway for age-related macular 
de gen eration using iPS cell-derived RPE cells.[39] It is likely, however, that 
an increasing number of clinical trials will follow, including the use of iPS-
derived dopamine-releasing neurons in patients with Parkinson’s disease.
The question arises as to whether pluripotent cells should be 
governed by the same regulations that apply to other cell-based 
products given their unique characteristics and the processes used 
for their derivation. With regard to their derivation, ES cells will be 
governed by legislation that governs the use of human embryos. This 
does not apply to iPS cells. With regard to clinical trials, both cell types 
and their derivatives would be subjected to the same rules that apply 
to all clinical trials. In the SA context, these are clearly spelled out in 
the general regulations made in terms of the Medicines and Related 
Substances Control Act 101 of 1965.[40]
Conclusion
With the exception of reproductive cloning, which is banned globally, 
research on human embryos including SCNT, the derivation of ES cells 
and therapeutic cloning are all permissible according to SA legislation, 
but according to the NHA and regulations thereto, require ministerial 
authorisation. Specific matters on which the NHA is silent include egg 
donation for research purposes, iPS cells and genome editing of pre-
implantation embryos. 
With regard to the use of pluripotent cells or their derivatives 
for therapeutic purposes, since this is still experimental in nature it 
would be governed by the rules that apply to clinical trials. These cells 
would fall under the section of ‘biological medicines’ in the Guidelines 
to the Registration of Medicines,[41] to be read in conjunction with 
the Medicines and Related Substances Act and its regulations. This 
includes, among others, registration with the Medicines Control 
Council and approval from a registered research ethics committee 
(which implies peer review). Furthermore, patients should not have 
to pay for these experimental forms of treatment.
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Annexure
Definitions from the National Health Act and Regulations 
Name Definition Source Comment / proposal
DNA deoxyribonucleic acid, which is a 
nucleic acid, composed of building 
blocks called nucleotides




the sub-cellular component that 
contains human genetic information
deoxyribose nucleic acid which is a 
nucleic acid composed of building 
blocks called nucleotides
Regulations relating to the import and export of 
human tissue, blood, blood products, cultured 
cells, stem cells, embryos, fetal tissue, zygotes and 
gametes
(No. R. 181)
chromosome a thread-like structure made up of 
DNA found in the nucleus of all cells
Regulations relating to the use of human 
biological material
(No. R. 177)
Note: only visible during cell 
division
gamete either of the two generative cells essential 
for human reproduction
National Health Act
(No. 61 of 2003)
oocyte developing human egg cell National Health Act
(No. 61 of 2003)
the female gamete Regulations relating to artificial fertilisation of 
persons 
(No. R. 175)
sperm the male gamete Regulations relating to artificial fertilisation of 
persons 
(No. R. 175)
Not defined in the Act
zygote the product of the union of a male and 
a female gamete
National Health Act
(No. 61 of 2003)
polar body a product that is formed during the 
development of the female gamete 
(during meiosis), which contains little 
cytoplasm and a haploid number of 
chromosomes
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Annexure (continued)
Definitions from the National Health Act and Regulations
Name Definition Source Comment / proposal
gonad human testis or human ovary National Health Act
(No. 61 of 2003)
embryo a human offspring in the first 8 weeks 
from conception
National Health Act
(No. 61 of 2003)
Use of the word ‘offspring’ is 
inappropriate.
Proposal – replace with: the early 
stages of human growth and 
development, from conception to the 
eighth week
a human offspring in the first 8 weeks 
of conception
Regulations relating to the import and export of 
human tissue, blood, blood products, cultured 
cells, stem cells, embryos, fetal tissue, zygotes 
and gametes
(No. R. 181)
Use of the word ‘offspring’ is 
inappropriate.
Use of the phrase ‘of conception’ 
is inappropriate as conception is 




tissue from an embryo Regulations relating to the import and export of 
human tissue, blood, blood products, cultured 
cells, stem cells, embryos, fetal tissue, zygotes 
and gametes
(No. R. 181)
blastocyst a pre-implantation embryo consisting of 
an outer layer, which forms the placenta 
and a 30 to 200-cell inner cell mass, which 
develops into the fetus
Regulations relating to artificial fertilisation of 
persons 
(No. R. 175)
fetus a human offspring from 8 weeks after 
conception until birth
Regulations relating to the use of human 
biological material
(No. R. 177)
Use of the word ‘offspring’ is 
inappropriate
a human offspring from 8 weeks after 
conception until birth
Regulations relating to the import and export of 
human tissue, blood, blood products, cultured 
cells, stem cells, embryos, fetal tissue, zygotes 
and gametes
(No. R. 181)
Use of the word ‘offspring’ is 
inappropriate
fetal tissue tissue from a fetus Regulations relating to the import and export of 
human tissue, blood, blood products, cultured 





stem cells found in the gonad of a 
fetus capable of becoming ova or 
sperm





any cell from the 30-200 inner cell 
mass of the blastocyst




cloning of a 
human being
the manipulation of genetic material 
in order to achieve the reproduction of 
a human being and includes nuclear 
transfer or embryo splitting for such 
purpose
National Health Act
(No. 61 of 2003)
Section 57(6)(a)
Proposal – replace with:
the manipulation of cells, gametes, 
zygotes or embryos or genetic material 
derived therefrom in order to achieve 
the reproduction of a human being 
and includes but is not limited to 
nuclear transfer and embryo splitting
therapeutic 
cloning
the manipulation of genetic material 
from either adult, zygotic or embryonic 
cells in order to alter, for therapeutic 
purposes, the function of cells or tissues
National Health Act
(No. 61 of 2003)
Section 57(6)(b)
Definition should include
somatic cell nuclear transfer
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